Literature DB >> 10893314

Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

W C Stevens1, R M Jones, G Subramanian, T G Metzger, D M Ferguson, P S Portoghese.   

Abstract

The indole moiety in the delta-opioid antagonist, naltrindole (2, NTI), was employed as a scaffold to hold an "address" for interaction with the kappa-opioid receptor. The attachment of the address to the 5'-position of the indole moiety was based on superposition of NTI upon the kappa antagonist, norbinaltorphimine (1, norBNI). A variety of cationic groups were employed as a kappa address in an effort to investigate its interaction with the anionic address subsite, Glu297, on the kappa receptor. Some of the groups that were employed for this purpose were amines, amidines, guanidines, and quaternary ammonium. Members of the series were found to have a varying degree of kappa antagonist potency and kappa selectivity when tested in smooth muscle preparations. The 5'-guanidine derivative 12a (GNTI) was the most potent member of the series and had the highest kappa selectivity ratio. GNTI was 2 times more potent and 6-10-fold more selective than norBNI (1). In general, the order of potency in the series was: guanidines > amidines approximately quaternary ammonium > amines. The kappa antagonist potency appeared to be a function of a combination of the pK(a) and distance constraint of the cationic substituent of the ligand. Receptor binding studies were qualitatively in agreement with the pharmacological data. Molecular modeling studies on 12a suggested that the protonated N-17 and guanidinium groups of GNTI are associated with Asp138 (TM3) and Glu297 (TM6), respectively, while the phenolic hydroxyl may be involved in donor-acceptor interactions with the imidazole ring of His291. It was concluded that the basis for the high kappa selectivity of GNTI is related both to association with the nonconserved Glu297 residue and to unfavorable interactions with an equivalent position in mu- and delta-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893314     DOI: 10.1021/jm0000665

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

Review 2.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

3.  N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

Authors:  F Ivy Carroll; Sachin Chaudhari; James B Thomas; S Wayne Mascarella; Kenneth M Gigstad; Jeffrey Deschamps; Hernán A Navarro
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

Review 4.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).

Authors:  Pauline W Ondachi; Chad M Kormos; Scott P Runyon; James B Thomas; S Wayne Mascarella; Ann M Decker; Hernán A Navarro; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  J Med Chem       Date:  2018-08-29       Impact factor: 7.446

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

7.  Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation.

Authors:  I Obara; J Mika; M K-H Schafer; B Przewlocka
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Authors:  Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem       Date:  2008-12-14       Impact factor: 3.641

10.  Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system.

Authors:  Arati Kreibich; Beverly A S Reyes; Andre L Curtis; Laurel Ecke; Charles Chavkin; Elisabeth J Van Bockstaele; Rita J Valentino
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.